We are live on ! Find out more
JSPRW

Japer Therapeutics Warrants
JSPRW

Delisted

JSPRW was delisted on the 24th of September, 2026.

Back to rankings

7 hedge funds and large institutions have $187K invested in Japer Therapeutics Warrants in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

50% less capital invested

Capital invested by funds: $372K → $187K (-$185K)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$9
2
SIA
SkyView Investment Advisors
New Jersey
+$5

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$618
2
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$2

JSPRW Hedge Fund Activity: Q2 2026 in Review

7 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2026, worth a combined $187K — down 50% from $372K a quarter earlier.

Fund positioning in JSPRW was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Wolverine Asset Management, adding an estimated $9. The largest seller was Susquehanna International Group, exiting entirely with an estimated $618 sold.

  • 7 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $187K of Japer Therapeutics Warrants stock for Q2 2026, down 50% quarter-over-quarter.
  • 1 fund opened new Japer Therapeutics Warrants positions in Q2 2026 and 1 closed out, a net change of 0 holders.
  • The largest Japer Therapeutics Warrants buyer in Q2 2026 was Wolverine Asset Management, an estimated $9 added.
  • The largest Japer Therapeutics Warrants seller in Q2 2026 was Susquehanna International Group, an estimated $618 sold.

Based on aggregated 13F filings for Q2 2026.